Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An antibody-drug conjugate could be a step toward selective treatment for neuroendocrine prostate cancer.
Scientists studied the drug, BO-112, using lab dish experiments and a mouse model of melanoma.
He battled Stage IV pancreatic cancer for 18 months.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
Tumors with large numbers of genetic mutations may be especially susceptible to treatment with immunotherapy.
BO-112 helped make tumor cells more vulnerable to immunotherapy, offering a possible treatment route for hard-to-treat cancers.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
The checkpoint inhibitor is approved for adults and children with relapsed lymphoma.
When you are still alive with Stage IV lung cancer fourteen years after being diagnosed, people want to know why.
The report highlights how cancer research is extending and improving lives and includes a special feature on COVID-19 and cancer challenges.
The immunotherapy combo improved overall survival compared with chemotherapy.
Adding Tecentriq to a three-drug chemotherapy regimen increases odds of remission of early-stage triple-negative breast cancer.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.